The mechanism of streptomycin action in tuberculosis still appears to be an open question. Although from the first suggestion of its use for treating tuberculous man, it was taken for granted that its action was simply that of a tuberculostatic agent in vivo, simulating the action noted in vitro in certain culture tests under definitely established conditions. There were a few enthusiasts who led one to infer that streptomycin could kill tubercle bacilli readily and directly in vivo5 as well as in vitro.7 Such simple action would certainly prove highly desirable in achieving a cure for tuberculosis, but unfortunately it takes into little account the multiple problems involved in the various reactions of the tubercle bacillus and the similarities upon which are based its parasitism in the human or animal body. These mechanisms are also far from being completely elucidated. Extreme caution is necessary to avoid hasty deductions, if past experiences with the tubercle bacillus and tuberculosis are used as evidence.
In a preliminary report2 in 1946, it was pointed out that:
Streptomycin properly administered and in proper dosage is capable of retarding the development or growth of human tubercle bacilli both in vitro... and in vivo. The concentration of streptomycin required to retard the growth of tubercle bacilli in vitro in good nutrient mediums can only be attained in vivo for a brief period by any route of administration or amount of streptomycin that can be used. There is no evidence available . . . to indicate that streptomycin enters the important organs in appreciable amount for any significant time, although it is present in the blood, or that it accumulates in these organs. There is no evidence that tubercle bacilli adsorb or absorb streptomycin or that it accumulates in these bacilli in vitro or in vivo.
not appear to act in tuberculosis as a simple chemotherapeutic retardant, as it does in the test tube, but that there is a threshold of remote sustained action. When initiated minimally, the effect persists for some time; above the maximum threshold effect, it is needless to continue forcing treatment, since the benefit derived does not exceed that of the established maximum."
With a view to extend the information on the mechanisms of action of streptomycin in tuberculosis further, a series of controlled in vitro and in vivo tests with tubercle bacilli in various mediums as well as controlled animal tests were performed and will be presented briefly.
In vitro studies It has been shown that streptomycin definitely has its limitations even as a retardant to the growth of human tubercle bacilli, particularly when planted on a good nutrient medium and especially one containing egg. Even slight modifications in simple mediums or in variation of amount of plants serve to change markedly the unit-retarding values of streptomycin for tubercle bacilli. To note whether streptomycin is destroyed, adsorbed, or inactivated in egg mediums, which might account for its lack of action on the growth of tubercle bacilli in these mediums, varying amounts of streptomycin were added to egg-white and egg-yolk before coagulation sterilization. Then known weights of the medium were tested for streptomycin content against a known acid-fast saprophyte (Day) sensitive to small amounts (1 unit) of streptomycin on glycerol agar and glycerol broth mediums. These mediums disclosed a full value of free streptomycin action, and this was readily diffusible and soluble in the simple test mediums (Fig. 1) .
In order to determine the effect of different amounts of streptomycin in vitro at 370 C. upon a virulent strain of human tubercle bacilli (#4008), both in regard to viability and resistance development, an experiment was performed and is presented briefly in Table 1 .
The findings recorded in Table 1 indicate that up to 1000 units of streptomycin brought in contact with virulent human tubercle bacilli do not destroy the bacilli during exposure at 370 C. in a buffered nonnutrient simple synthetic non-protein medium for four weeks. It is evident, however, that in the direct transfer, especially with 100 units per cc. and 1000 units per cc. of streptomycin, sufficient is carried onto the yolk nutrient medium to retard the growth; but when diluted to 1:1000 (0.001 mg.) growth occurs without apparent retardation. It is also apparent that such exposure to 1000 units of streptomycin per cc. does not alter the bacilli sufficiently to change their growth ability either on nutrient broth medium or on yolk medium containing various concentrations of streptomycin up to 1000 units per cc. There is no evidence from this study that the original bacilli develop resistance to streptomycin or that they contain a resistant variant-making it appear likely that resistance development to streptomycin is a factor of multiplication of the bacilli and inherent in the progeny and adaptation rather than a change in the original bacilli themselves.
Infection experiments with guinea-pigs, in elaboration of the above culture tests, also disclosed that exposure of virulent human tubercle bacilli in non-nutrient Wong's medium kept at 370 C. and containing amounts of streptomycin up to 1000 units per cc. for a period as long as one month did not produce any change in the bacilli. This indicates that the resistance of the bacilli has not been altered sufficiently to prevent streptomycin treatment (using 5000 to 25,000 units of tSome of these guinea-pigs revealed no evident macroscopic tuberculosis, although cultures from all the organs were distinctly positive. streptomycin per day) of the guinea-pigs infected with these bacilli from showing a definite retardation of their tuberculosis. Controls infected with streptomycin-resistant bacilli (resistance of the bacilli produced in vitro) showed no appreciable effect under similar streptomycin treatment. This is shown in Table 2 .
It is apparent from the results recorded in Table 2 that prolonged contact, up to one month at 370 C., with up to 1000 units of streptomycin per cc. does not alter appreciably the streptomycin resistance of virulent human tubercle bacilli as determined by controlled guinea-pig infection and streptomycin-treatment tests. Also streptomycin does not affect infection in guinea-pigs with streptomycin-resistant strains of virulent human tubercle bacilli as far as can be determined, verifying previous observations.6 '9 In view of the action in vivo of intermittent treatment with streptomycin for retarding tuberculosis in the guinea-pig,3 it appeared desirable to study the effect of intermittent exposure to varying amounts of streptomycin per cc. in a simple nutrient medium (glycerol broth) suited both to growing tubercle bacilli and to the adequate in vitro action of streptomycin without evident unit disturbance. In a suitably constructed apparatus for this purpose in which the medium could be changed from streptomycin-containing to streptomycin-free nutrient at varying intervals, the results recorded in Table 3 were obtained with a human tubercle bacillus. t 0 = absence of growth, and ± = definite macroscopic growth. I The absence of growth with the 1000 units per cc. amounts of streptomycin is accounted for by the inability in the apparatus used to remove all trace of streptomycin completely in the streptomycin-free period, since the nutrient medium for such culture period was found to contain by analysis in excess of 1 to 5 units of streptomycin per cc. shortly after the experiment was initiated. § These cultures were all surface planted, and the daily disturbance of the plants played a significant part in the absence of growth here.
The results recorded in Table 3 indicate that intermittent exposure in vitro to streptomycin in concentrations up to 100 units per cc. in glycerol broth medium, suited to continuing unit evaluation retardation against the human tubercle bacillus, is without evident retardation effect toward the growth of the bacilli if exposure to the streptomycin is less than every other day. Therefore, unless some other mechanism is at the basis of the remote threshold retardant action noted in the animal (guinea-pig), the simple retardant in vitro effect of streptomycin cannot be translated directly into in vivo action upon the growth of the tubercle bacilli. In addition, these experiments provide further evidence that streptomycin is not adsorbed or absorbed in active form by the tubercle bacilli.
In vivo studies From the in vitro studies, it would appear that mammalian tubercle bacilli may develop resistance to streptomycin, especially under conditions where growth is possible, even though retardation occurs; retardation in even relatively large concentrations of streptomycin is only partial; and that streptomycin within reasonable limits of concentration will not kill tubercle bacilli. In addition, in vitro retardation is contingent upon the presence of streptomycin in retarding amounts under the conditions in which retardation can actually take place. This poses the problem of the relation of the in vitro growth of tubercle bacilli and in vivo retardation of tuberculosis as influenced by streptomycin. Chemical and biological studies of the persistence and excretion of streptomycin following injection suggest that repeated administrations are required at less than 24-hour intervals to attain a constant level of possible active retarding amount in the body, and yet injections spaced from 5-to 10-day intervals reveal a significant retardation of tuber- 
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culosis produced by infecting guinea-pigs with highly virulent mammalian tubercle bacilli. From these observations, it would appear that direct retardation of the growth of the bacilli cannot be translated into the effects noted in vivo.
In order to elucidate further the in vivo retardation of tuberculosis by streptomycin administration, various controlled tests were performed as follows to aid in the solution of this problem: large doses of streptomycin were given repeatedly to maintain a high concentration in the blood during the early periods of intravenous infection to see if it would affect the bacilli so far as their recovery from the organs could be determined. The guinea-pigs were given an intravenous injection of 1 mg. of virulent human tubercle bacilli (#4008)) and streptomycin Table 4 . The findings recorded in Table 4 indicate that brief treatment with streptomycin in large amounts does not influence the recovery of virulent human tubercle bacilli from the organs of the guinea-pig following intravenous injection.
In order to elaborate further on the foregoing findings, the persistence of the bacilli in the blood after intravenous injection of 1 mg. was studied over a four-week interval of streptomycin treatment. For this purpose both avirulent and virulent human tubercle bacilli were used in gunea-pigs. The results are given briefly in Table 5 .
The findings recorded in Table 5 indicate that streptomycin treatment with large daily doses for one month does not influence the rate of disappearance of either avirulent or virulent human tubercle bacilli following intravenous injection. It is evident from the foregoing experiments, summarized in Tables 4 and 5 , that such effect as occurs on tuberculosis as a result of streptomycin treatment cannot be attributed either to a change in the persistence of the bacilli in the blood or an alteration of the organic presence of the bacilli in viable form after intravenous injection.
In additional experiments in which infection was produced by the intravenous injection of 0.000,001 mg. of virulent human tubercle bacilli, it was found that although the tuberculosis is retarded perceptibly by one month of intensive treatment with streptomycin (25,000 units daily) this does not destroy the tubercle bacilli and the animals eventually die of evident and marked macroscopic tuberculosis. This infecting dose borders on the minimum, and yet one month of intensive treatment with streptomycin (equivalent on a proportionate weight basis to far more than can be administered to man safely) did not destroy the bacilli in the body.
In order to note the effect of continuous daily administration of different amounts of streptomycin upon lethal tuberculosis produced by the intravenous injection of 1 mg. of fine suspension of virulent human tubercle bacilli, a series of guinea-pigs was treated until death, or up to 250 days, with the results recorded in Table 6 .
It is evident from the findings recorded in Table 6 that daily administration of streptomycin up to 10 mg. per day for 250 days did not prevent a lethal outcome following intravenous infection and that such effect appeared to be graded, dependent upon the amount of streptomycin used, from 1 mg. up to 10 mg. This effect could not be en- Table 7 . The findings in Table 7 disclose the interesting fact that treatment with streptomycin exerts very little effect for the first five days, even when large doses are used; but after this time, a definite beneficial effect is noted which becomes particularly marked in the interval from the 11th to the 15th days after intravenous infection. From this it appears likely that the direct action of the streptomycin on the bacilli should be more evident in the early periods of infection as a preventive of multiplication of the bacilli or their initiation of growth. However, since the effect is more significant at the period of tubercle formation, there appears to be a more prominent effect on tuberculosis rather than on the tubercle bacillus per se. This effect of streptomycin is further emphasized when considering the results of intracutaneous infection and lesions since they can be studied from inception throughout the period. When guinea-pigs are given suitable intracutaneous injections of virulent human tubercle bacilli (0.01 mg.), a striking effect of the treatment is noted with large subcutaneous daily amounts (25 mg.) of streptomycin. A typical experiment of this type is presented in Chart 1 which depicts the composite size of and evolution of the skin lesions of three guinea-pigs for each curve. ZHf9ealed.
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The findings recorded in Chart 1 show that streptomycin retards the development of the skin lesion resulting from the intracutaneous injection of virulent tubercle bacilli and consequently tends to prevent ulceration and hastens healing. However, when the animals are killed after more than 100 days of streptomycin treatment, many of them show evident tuberculosis of the draining lymphatic glands and internal organs, and this is particularly evident in animals when treatment is begun after the establishment of the skin lesion (21 days after infection), in spite of the evident general retardation of the tuberculosis by the streptomycin treatment. When viable or non-viable avirulent human tubercle bacilli (in amounts of 0.1, 0.01, and 0.001 mg.) are used by intracutaneous injection to produce the skin lesions, the effect is still strikingly evident. Since no multiplication of the bacilli is involved in this reaction, it suggests that the action of streptomycin does not appear to be one of direct retardation of the growth of the bacilli in vivo but rather an indirect action against the effect of the bacilli. This is depicted in graph form in Chart 2 for the non-immune, non-allergic guinea-pigs and in Chart 3 for the immune and allergic guinea-pigs. ONoduIe. A -O. 9 Heca-ed -7Treated with Z5,000 vrz its sciepto'syein. da~i3,. ---Conerot. CHART 3 From these studies it would appear that streptomycin retards the development of the skin lesions resulting from the intracutaneous injection of viable and non-viable avirulent human tubercle bacilli as well as delaying their appearance. In the tuberculo-immune and tuberculoallergic guinea-pig, the streptomycin exerts no effect upon the time of appearance of the reaction produced toward the injection of tubercle bacilli, but does affect slightly the amount of reaction and size of the final lesion produced by the tubercle bacilli in the skin of such animals.
Large amounts of tubercle bacilli, dead or viable avirulent, produce no distinct tuberculosis of the internal organs when given intravenously 194 in fine suspension, but find expression mainly after the initial transient reactions as a marked splenomegaly, reaching a maximum in about two months and depending on dosage, after which resolution of the splenomegaly occurs. In view of the foregoing fact, it appeared of interest to note what effect, if any, streptomycin might exert on maximum intravenous infections with fine suspensions of virulent human tubercle bacilli (#4008). The results of such an experiment, which might be considered forced scientific experimentation to gain explanatory information if possible, are presented in Table 8 . Table 8 that streptomycin in large amounts (25 mg. daily) exerts only a marked effect in prolonging the life of the guinea-pig infected intravenously with large amounts (25 to 100 mg.) of virulent human tubercle bacilli, but tuberculosis is markedly evident provided enough time has elapsed after injection of the bacilli. The general impression gained from such tests is that large numbers of bacilli per se are of little harm to the animal, but the reaction to these bacilli appears to be the significant factor against which streptomycin exerts an influence. The foregoing suggested an elaboration of these findings, using viable avirulent human tubercle bacilli in large amounts in fine suspension intravenously in place of the virulent bacilli used above. The findings are recorded in Table 9 giving the splenic weights, the spleen being the significant organ of deposit in the guinea-pig for intravenously injected avirulent bacilli. The findings recorded in Table 9 are suggestive of a pronounced suppressive effect of streptomycin upon the splenic reaction in the guinea-pig following the intravenous injection of large amounts (100 mg.) of fine suspensions of avirulent human tubercle bacilli.
In further extensive experiments to disclose the exact site of streptomycin action, the reticulo-endothelial system was given consideration. Briefly, this system was overloaded by using large amounts of India ink and viable avirulent human tubercle bacilli, and then the effect of streptomycin treatment in large amounts (25 mg. daily) was noted. It was found that such treatment with India ink or avirulent bacilli did not interfere with the normal lethal outcome following the intravenous injection of 1 mg. of virulent human tubercle bacilli nor did it interfere in any way discernible with the retardant effect of the streptomycin on the tuberculosis. In many experiments to determine the effect of streptomycin on established experimental tuberculosis, it was found that any interpretation placed on the resolution of tuberculosis was a matter of opinion entirely. Both the time element and the vagaries of this disease, especially following virulent subcutaneous or intracutaneous infections, lead to a variety of results involved in the immune and allergic phenomena and in the matter of the variegated spread, both local and general, so that the amount of tuberculous involvement at the start of treatment, and based on the natural curve of resolution, could hardly be standardized. It is well known that even after graded local infections with small, immediately non-lethal, amounts of virulent human tubercle bacilli the variation, both as to amount and spread of tuberculosis, is so great that any controls border on the difficulties encountered with decisive human experimentation in tuberculosis.8 So far as we were able to interpret, it did not appear that resolution of tuberculosis in a satisfactorily controlled manner was produced by streptomycin treatment, but that such effect as might be seen was involved in partial retardation of tuberculosis which consequently would lead to a favorable comparison when using progressive controls for this purpose.
In order to gain a further insight into the action mechanism not only of streptomycin but also of tuberculosis not previously discernible without the aid of streptomycin, or other in vivo retardants, guineapigs were treated with virulent infection coincidently, after, and during immunization with avirulent and virulent human tubercle bacilli. A summarized table is presented.
The findings recorded in Table 10 indicate that streptomycin treatment in large amounts (25 mg. daily) does not interfere with development of specific tuberculo-immunity nor with the development of specific tuberculo-allergy or its bacillary intoxication phase.' It is of interest scientifically, however, that in spite of the absence of macroscopic tuberculosis to account for the death of some of the intravenously infected and streptomycin-treated guinea-pigs the injection of the virulent human tubercle bacilli results lethally though retardation of death has occurred. This is not to be accounted for by the existence of a bacteremia, and the bacilli recovered from these guinea-pigs all proved to be relatively streptomycin resistant. Another feature of scientific interest is noted in the fact that when guinea-pigs are immunized by streptomycin suppression of virulent bacillary tuberculosis and then followed by a second intravenous injection of the same amount of virulent human tubercle bacilli, practically all the guinea-pigs that recovered from the bacillary allergic intoxication caused by the second injection revealed marked (4-plus) tuberculosis of the organs at the time of death. On the other hand, immunization of guinea-pigs with avirulent bacilli given intravenously and during streptomycin treatment,
